Strategy Shares Nasdaq 5 Handl Index ETF (FIVR)
- Previous Close
21.15 - Open
21.12 - Bid --
- Ask --
- Day's Range
21.12 - 21.15 - 52 Week Range
20.20 - 21.77 - Volume
20 - Avg. Volume
455 - Net Assets 2.15M
- NAV 21.15
- PE Ratio (TTM) 19.87
- Yield 4.89%
- YTD Daily Total Return 6.65%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.88%
The fund will invest at least 80% of its assets in securities of the index. The index generally consists of securities issued by exchange-traded funds (“ETFs”) and is split into two components, with a 50% allocation to fixed income and equity ETFs (the “Core Portfolio”) and a 50% allocation to ETFs of 12 asset categories (the “Explore Portfolio”).
Strategy Shares
Fund Family
Conservative Allocation
Fund Category
2.15M
Net Assets
2021-12-28
Inception Date
Performance Overview: FIVR
Trailing returns as of 9/1/2023. Category is Conservative Allocation.
Holdings: FIVR
Top 10 Holdings (79.12% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: FIVR
Lowering target price to $9.00
MEDICAL PROPERTIES TRUST INC has an Investment Rating of BUY; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetIntellia Therapeutics' Gene Editing Pipeline Looks Promising; Shares Undervalued
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
RatingPrice TargetRaising target price to $13.00
MEDICAL PROPERTIES TRUST INC has an Investment Rating of BUY; a target price of $13.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about MPW?
MEDICAL PROPERTIES TRUST INC has an Investment Rating of BUY; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target